A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with outside investigators, has discovered a new pathway of inflammation-driven cancer development. Their findings, “Initiation of Inflammatory Tumorigenesis by CTLA4 Insufficiency Due to Type 2 Cytokines,” were published online on January 26 by the Journal of Experimental Medicine.
Scientists in the international Illuminating the Druggable Genome (IDG) project, including the University of Miami Miller School of Medicine, are taking an unprecedented approach to discovering new medical therapies. They’re exploring the 38 percent of the human genome that is considered “dark” or largely untapped – so far -- for potential new drug targets.
Although it has been nearly 50 years since Stuart R. Weiss, M.D. ’71, graduated from the University of Miami School of Medicine, he is still dedicated to ensuring the future of his medical alma mater. Weiss, an endocrinologist, has been a generous supporter of the medical school for more than 40 years. His first gift to the school came just three years after graduation.
In hopes of finding new ways to potentially prevent the debilitating effects of arthritis in different regions of the ankle, Amiethab A. Aiyer, M.D., chief of the Foot & Ankle Service and assistant professor in the University of Miami Miller School of Medicine’s Division of Orthopaedic Surgery, recently received a prestigious research grant from the American Orthopaedic Foot & Ankle Society (AOFAS).
Barbara A. Vance, Ph.D., CRA, will join Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine on March 17 as assistant vice president and associate director for administration. Vance will be a senior member of Sylvester’s leadership team, responsible for efficient operations and financial performance, including submission of the National Cancer Institute (NCI) Cancer Center Support Grant.